Metformin treatment for small benign thyroid nodules in patients with insulin resistance

Metabolic Syndrome and Related Disorders

Volumn 9, Issue 1, 2011, Pages 69-75

  Rezzónico, Jorge ^a   Rezzónico, Mariana ^a   Pusiol, Eduardo ^a   Pitoia, Fabian ^a   Niepomniszcze, Hugo ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; METFORMIN; THYROTROPIN;

ADULT; ARTICLE; ASPIRATION BIOPSY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HOMEOSTASIS; HORMONE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; THYROID NODULE;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; MIDDLE AGED; THYROID NODULE; THYROXINE; TUMOR BURDEN; YOUNG ADULT;

EID: 79955501998     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2010.0026     Document Type: Article

References (35)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607. (Pubitemid 19004941)
2. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-578. (Pubitemid 351232031)
3. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003;26:3320-3325. (Pubitemid 37466894)
4. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin N Am 2004;33:283-303. (Pubitemid 38680631)
5. Rezzonico J, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Introducing the thyroid gland as another victim of the insulin resistance syndrome. Thyroid 2008;18:461-464. (Pubitemid 351519543)
6. Ayturk S, Gursoy A, Kut A, Anil C, Nar A, Tutuncu NB. Metabolic syndrome and its components are associated with increased thyroid volume and nodule prevalence in a mildto- moderate iodine-deficient area. Eur J Endocrinol 2009;161: 599-605.
7. Rezzónico JN, Rezzónico M, Pusiol E, Pitoia F, Niepomniszcze H. Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab Syndr Relat Disord 2009;7:375-380.
8. Gursoy A. Rising thyroid cancer incidence in the world might be related to insulin resistance. Med Hypotheses 2009;74:35-36.
9. Rezzónico JN, Rezzónico M, Pusiol E, Pitoia F, Niepomniszcze H. High prevalence of thyroid nodules in patients with achrocordons (skin tags). Possible role of insulin resistance. Medicina (B Aires) 2009;69:302-304.
10. Saborido L, Latres de Rauek B, Rezzonico JN, Guntsche Z, Cabut V, Leiva R, Munoz P, Bidot L, Vitoria C, Rosso. A Iodine in schoolchildren. Relationship with incidence of goiter, socioeconomic group and salt intake. Medicina (B Aires) 1996;56:448-454. (Pubitemid 127540501)
11. Hegedüs L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev 2003;24:102-132.
12. Derwahl M, Studer H. Pathogenesis and treatment of multinodular goiter. In: Fagin JA (ed). Thyroid Cancer. Boston/ Dordrecht/London: Kluwer; 1998:155-186.
13. Studer H, Derwahl M. Mechanisms of nonneoplastic endocrine hyperplasia- a changing concept: A review focused on the thyroid gland. Endocr Rev 1995;16:411-426.
14. Westermark K, Karlsson FA, Westermark B. Thyrotropin modulates EGF receptor function in porcine thyroid follicle cells. Mol Cel Endocrinol 1985;40:17-23. (Pubitemid 15113137)
15. Eggo MC, Bachrach LK, Burrow GN. Interaction of TSH, insulin and insulin-like growth factors in regulating thyroid growth and function. Growth Factors 1990;2:99-109. (Pubitemid 20057748)
16. Hofbauer LC, Rafferzeder M, Janssen OE, Gartner R. Insulin-like growth factor I messenger ribonucleic acid expression in porcine thyroid follicles is regulated by thyrotropin and iodine. Eur J Endocrinol 1995;132:605-610.
17. Burikhanov R, Coulonval K, Pirson I, Lamy F, Dumont JE, Roger PP. Thyrotropin via cyclic AMP induces insulin receptor expression and insulin co-stimulation of growth and amplifies insulin and insulin-like growth factor signaling pathways in dog thyroid epithelial cells. J Biol Chem 1996; 271:29400-29406. (Pubitemid 26382658)
18. Eggo MC, King WJ, Black EG, Sheppard MC. Functional human thyroid cells and their insulin-like growth factorbinding proteins: regulation by thyrotropin cyclic 39,59 adenosine monophosphate, and growth factors. J Clin Endocrinol Metab 1996;81:3056-3062. (Pubitemid 26323908)
19. Clark R. The somatogenic hormones and insulin-like growth factor-1: Stimulators of lymphopoiesis and immune function. Endocr Rev 1997;18:157-179. (Pubitemid 27171518)
20. Cheung NW, Boyages SC. The thyroid gland in acromegaly: An ultrasonographic study. Clin Endocrinol (Oxf) 1997;46: 545-549. (Pubitemid 27286926)
21. Gharib H, Mazzaferri EL. Thyroxine suppressive therapy in patients with nodular thyroid disease. Ann Inter Med 1998; 128:386-394. (Pubitemid 28103108)
22. Hansen JM, Kampmann J, Madsen SN, Skovsted L, Solgaard S, Grytter C, Grøntvedt T, Rasmussen SN. L-Thyroxine treatment of diffuse non-toxic goitre evaluated by ultrasonic determination of thyroid volume. Clin Endocrinol (Oxf) 1979; 10:1-6. (Pubitemid 10173054)
23. Perrild H, Hansen JM, Hegedüs L, Rytter L, Holm B, Gundtofte E, Johansen K. Triiodothyronine and thyroxine treatment of diffuse non-toxic goitre evaluated by ultrasonic scanning. Acta Endocrinol (Copenh) 1982;100:382-387. (Pubitemid 12075346)
24. Bongers H, Hotze LA, Schmitz R, Joseph K. LT4-monopreparation vs. LT4-LT3-compound preparation in the treatment of diffuse endemic goitre. Acta Endocrinol (Copenh) 1986;113:242-248. (Pubitemid 16006648)
25. Wilders-Truschnig MM, Warnkross H, Leb G, Langsteger W, Eber O, Tiran A, Dobnig H, Passath A, Lanzer G, Drexhage HA. The effect of treatment with levothyroxine or iodine on thyroid size and thyroid growth stimulating immunoglobulins in endemic goitre patients. Clin Endocrinol (Oxf) 1993;39:281-286. (Pubitemid 23274426)
26. Gullu S, Gurses MA, Baskal N, Uysal AR, Kamel AN, Erdogan G Suppressive therapy with levothyroxine for euthyroid diffuse and nodular goiter. Endocrine J 1999;46:221-226. (Pubitemid 29197771)
27. Peters H, Hackel D, Schleusener H. Treatment of euthyroid struma. Comparable volume reduction with 400 micrograms iodine, 100 micrograms levothyroxine combined with 100 micrograms iodine or individually dosed levothyroxine. Medizinische Klinik (Munich) 1997;92:63-67. (Pubitemid 27107007)
28. Kreissl M, Tiemann M, Hanscheid H, Rendl J, Reiners C. Comparison of the effectiveness of two different dosages of levothyroxine-iodide combinations for the therapy of euthyroid diffuse goiter. Dtsch Med Wochenschr 2001;126: 227-231. (Pubitemid 32204769)
29. Papini E, Petrucci L, Guglielmi R, Panunzi C, Rinaldi R, Bacci V, Crescenzi A, Nardi F, Fabbrini R, Pacella CM. Longterm changes in nodular goiter: A 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab 1998;83: 780-783. (Pubitemid 28496445)
30. Berghout A, Wiersinga WM, Drexhage HA, Smits NJ, Touber JL. Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Lancet 1990;336:193-197. (Pubitemid 20229056)
31. Lima N, Knobel M, Cavaliere H, Sztejnsznajd C, Tomimori E, Medeiros-Neto G. Levothyroxine suppressive therapy is partially effective in treating patients with benign, solid thyroid nodules and multinodular goiters. Thyroid 1997;7: 691-697. (Pubitemid 28086199)
32. Wesche MF, Tiel-Van Buul MM, Lips P, Smits NJ, Wiersinga WM. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab 2001;86: 998-1005. (Pubitemid 32322972)
33. Vigersky RA, Filmore-Nassar A, Glass AR. Thyrotropin suppression by metformin. J Clin Endocrinol Metab 2006;91: 225-227. (Pubitemid 43069142)
34. Cappelli C, Rotondi M, Pirola I, Agosti B, Gandossi E, Valentini U, De Martino E, Cimino A, Chiovato L, Agabiti Rosei E, Castellano M. TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid and euthyroid on L-T4 therapy patients. Diabetes Care 2009;32:1589-1590.
35. Isidro ML, Penín MA, Nemiña R, Cordido F. Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. Endocrine 2007;32:79-82. (Pubitemid 350242550)